4-醛基四氢吡喃 | 50675-18-8

• 物质功能分类: 医药中间体 - 吡喃类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 中文名称: 4-醛基四氢吡喃
• 中文别名: 四氢呋喃-4-甲醛；四氢吡喃-4-甲醛
• 英文名称: 3,4,5,6-tetrahydro-2H-pyran-4-carbaldehyde
• 英文别名: tetrahydro-2H-pyran-4-carbaldehyde；tetrahydropyran-4-carbaldehyde；oxane-4-carbaldehyde；tetrahydro-2H-pyran-4-formaldehyde；4-Formyltetrahydropyran
• CAS: 50675-18-8
• 化学式: C₆H₁₀O₂
• mdl: MFCD03425264
• 分子量: 114.144
• InChiKey: CXLGNJCMPWUZKM-UHFFFAOYSA-N

物化性质

• 沸点：
  74-77 °C(Press: 11 Torr)
• 密度：
  1.096±0.06 g/cm3(Predicted)
• 闪点：
  >23℃

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25,S26,S36/37
• 危险类别码：
  R36,R20/21/22
• 海关编码：
  2932999099
• WGK Germany：
  3
• 危险性防范说明：
  P261,P301+P312,P302+P352,P304+P340,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  请保持冷静。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Formyltetrahydropyran
Synonyms: Tetrahydro-2H-pyran-4-carbaldehyde

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H319: Causes serious eye irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Formyltetrahydropyran
CAS number: 50675-18-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H10O2
Molecular weight: 114.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

四氢吡喃-4-甲醛是一种重要的有机合成中间体和医药中间体，广泛应用于实验室研发及化工、医药领域的研究过程中。

反应信息

• 作为反应物：
  描述：

  4-醛基四氢吡喃 在 palladium 10% on activated carbon 硫酸 、 氢气 作用下， 以 乙酸乙酯 、 甲苯 为溶剂， 50.0 ℃ 、300.01 kPa 条件下， 反应 78.0h， 生成 3-氧杂螺[5.5]十一烷-9-酮
  参考文献：
  名称：

  NEW 5-ALKYNYL-PYRIDINES

  摘要：

  本发明涉及一般式I的新的CGRP拮抗剂，其中R1、R2、R3、Ra、Rb、Rc、X、Y和Z的定义如下所述，各个对映体、各个对映体和其盐，特别是其与无机或有机酸或碱形成的生理上可接受的盐，含有这些化合物的药物、其用途以及其制备方法。

  公开号：

  US20120196872A1
• 作为产物：
  描述：

  N,N-dimethyltetrahydro-2H-pyran-4-carboxamide 在 sodium hydride 、 sodium iodide 作用下， 以 四氢呋喃 为溶剂， 以70%的产率得到4-醛基四氢吡喃
  参考文献：
  名称：

  氢化钠-碘化物复合物将N，N-二甲基羧酰胺还原为醛

  摘要：

  在温和的反应条件下，在碘化钠（NaI）存在下，使用氢化钠（NaH）建立了一种新的简洁的协议，用于将N，N-二甲基酰胺选择性还原为醛。具有NaH-NaI复合材料的本协议不仅可以还原具有广泛取代基相容性的芳族和杂芳族化合物，而且还可以还原脂肪族N，N-二甲基酰胺。在减少α-对映体酰胺的过程中，保留了α-手性。氘化钠（NaD）的使用为制备氘掺入率高的氘代醛提供了一种新的经济实惠的替代方法。NaH-NaI复合材料具有独特的化学选择性，可减少N，N-二甲基酰胺比酮。

  DOI：

  10.1002/hlca.201800049
• 作为试剂：
  描述：

  4-醛基四氢吡喃 、 (R)-tert-butyl 1-oxo-3-phenyl-1-(piperidin-4-ylmethylamine)propan-2-ylcarbamate 在 4-醛基四氢吡喃 作用下， 以88.4的产率得到(2-phenyl-1-(R)-((1-(tetrahydropyran-4-ylmethyl)piperidin-4-yl-methyl)carbamoyl)ethyl)carbamic acid tert-butyl ester
  参考文献：
  名称：

  [EN] PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES
  [FR] PROCÉDÉ DE PRÉPARATION DE L'IBODUTANT (MEN15596) ET INTERMÉDIAIRES APPARENTÉS

  摘要：

  本发明涉及一种新型合成ibodutant产品的方法，如下图所示，包括少量高产率步骤，使用具有低环境影响的试剂和溶剂，其特征是将两个部分化合物（3）和（4）耦合，其中一个（3）是通过将6-甲基-2-苯并[b]噻吩羧酸（1）与1-氨基-α-α-环戊烷羧酸偶联，随后与噁唑烷环化而合成的，而另一个化合物（4）则是通过适当的高选择性4-氨甲基哌啶（2）的官能化反应获得的。

  公开号：

  WO2010133306A1

文献信息

• 1-Amino 1H-imidazoquinolines
  申请人：Griesgraber W. George

  公开号：US20050054640A1

  公开（公告）日：2005-03-10

  1-Amino 1H-imidazoquinoline compounds, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

  1-氨基1H-咪唑喹啉化合物，含有该化合物的药物组合物，中间体，以及制备这些化合物的方法和将这些化合物用作免疫调节剂的方法，用于调节动物体内细胞因子生物合成，并用于治疗包括病毒性和肿瘤性疾病在内的疾病。
• [EN] BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE COMME INHIBITEURS DES BROMODOMAINES
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2016146738A1

  公开（公告）日：2016-09-22

  Compounds of formula (I) and salts thereof: wherein R1, R2, R3, R4 are defined herein. Compounds of formula (I) and salts thereof have been found to inhibit the binding of the BET family of bromodomain proteins to, for example, acetylated lysine residues and thus may have use in therapy, for example in the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis; and cancers.

  式（I）的化合物及其盐：其中R1、R2、R3、R4在此处定义。已发现式（I）的化合物及其盐能够抑制BET家族的溴结构域蛋白与例如乙酰化赖氨酸残基的结合，因此可能在治疗中发挥作用，例如在治疗自身免疫和炎症性疾病（如类风湿性关节炎）和癌症方面。
• [EN] AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS D'AZÉTIDIN-3-YLMÉTHANOL EN TANT QUE MODULATEURS DU RÉCEPTEUR CCR6
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：WO2021219849A1

  公开（公告）日：2021-11-04

  The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the treatment or prevention of various diseases, conditions or disorders.

  本发明涉及式(I)化合物，其合成以及作为CCR6受体调节剂用于治疗或预防各种疾病、状况或障碍。
• [EN] METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE<br/>[FR] PROCÉDÉS ET COMPOSÉS POUR LE TRAITEMENT D'UNE MALADIE GÉNÉTIQUE
  申请人：DESIGN THERAPEUTICS INC

  公开号：WO2021158707A1

  公开（公告）日：2021-08-12

  The present disclosure relates to compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.

  本公开涉及化合物和方法，用于调节dmpk的表达，并治疗dmpk发挥积极作用的疾病和病况。该化合物可以是一种转录调节分子，具有第一末端、第二末端和寡聚骨架，其中：a）第一末端包括一种DNA结合基团，能够非共价结合到核苷酸重复序列CAG或CTG；b）第二末端包括结合到调节分子的蛋白结合基团，该调节分子调节包含核苷酸重复序列CAG或CTG的基因的表达；c）寡聚骨架包括连接第一末端和第二末端的连接物。
• [EN] INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS<br/>[FR] COMPOSÉS D'INDAZOLE EN TANT QU'AGONISTES DE RÉCEPTEUR DE 5-HT4
  申请人：SUVEN LIFE SCIENCES LTD

  公开号：WO2015092804A1

  公开（公告）日：2015-06-25

  The present invention relates to novel indazole compounds of the Formula (I), wherein, R1 is alkyl or cycloalkyl; (Formula II) including their stereoisomers and their pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to 5-Hydroxytryptamine 4 (5-HT4) receptor agonists

  本发明涉及一种新型吲唑化合物，其化学式为（I），其中R1为烷基或环烷基；（化学式II），包括其立体异构体和药学上可接受的盐。本发明还涉及制备这种化合物的方法和包含这种化合物的药物组合物。本发明的化合物在治疗与5-羟色胺4（5-HT4）受体激动剂相关的各种疾病中是有用的。